Last updated on November 2017

A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients


Brief description of study

A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients

Detailed Study Description

To evaluate the safety and tolerability of a long-term enzyme replacement therapy(ERT) – PRX-102 – in adult subjects with Fabry disease.

Clinical Study Identifier: TX81187

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Caren Swift, RN, BSN

Baylor Scott & White Research Institute
Dallas, TX USA
  Connect »